Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Research & Development

Business Briefs: Merck and Forest Labs

May 23, 2013

Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement.
 

US awards GSK $200M to fight "superbugs"

May 23, 2013

GSK and the US Department of Health and Human Services inked a deal to fund development of new antibiotics, an area where clinicians face a dearth of new options.
 

Astellas shutters OSI and Perseid, lets 200 US staff go in R&D reorg

May 14, 2013

It was a particularly grim Monday for 200 Astellas employees in the US, who were informed that they were being let go and it was their last day with the company.
 

BMS scores "breakthrough" label for hep. C candidate

April 25, 2013

The regulatory coup means BMS gets to work with FDA to develop its home-grown hep. C cocktail, which is on a competitive track to another hep. C alliance with Merck.
 

Data show Gilead's sofosbuvir has 'clean' safety profile

April 24, 2013

Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.
 

Pfizer pipeline breast cancer drug gets fast tracked

April 11, 2013

FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.
 

Business briefs: BMS, Sanofi, UK Sunshine

April 08, 2013

BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
 

More pink slips at AstraZeneca

March 21, 2013

Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.
 

AstraZeneca consolidates R&D, moves US commercial roles

March 18, 2013

AstraZeneca is cutting 650 jobs in the US, "primarily in R&D," and consolidating its R&D operations at three "strategic R&D centers" in "bioscience clusters," academic and industrial beehives where the company can tap into concentrations of talent and infrastructure.
 

CMS releases "Sunshine" final rule: federal preemption, August start date

February 01, 2013

CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
 

AstraZeneca shakeup ousts commercial, R&D chiefs

January 15, 2013

AstraZeneca jettisoned its global head of commercial operations and R&D chief, eliminating their roles and curtly suctioning off the company's second-highest layer of management.
 

FDA Adcom eyes Invokana CV safety

January 09, 2013

The J&J diabetes drug seems effective in getting glucose down but may bump up bad cholesterol, raising a red flag for FDA advisory committee members.
 

Company news: Boehringer, Eli Lilly, Merck

January 07, 2013

Boehringer Ingelheim doubles down on one diabetes treatment, while parting ways on another; and Merck closes the year as a force in the start-up market.
 

Trial designed with crowd input gets FDA signoff

December 28, 2012

Transparency Life Sciences is tapping the wisdom of the crowd, with FDA's imprimatur, in an effort to make the drug development process more sustainable.
 

Study: Pharma getting more drugs approved, but less money for them

December 17, 2012

Researchers said the industry closed 2012 with a mixed bag of results. The upside: more approvals than last year. The downside: projected sales for these new drugs is less.
 

Company news: AstraZeneca, Alcon, Novo Nordisk

December 05, 2012

AstraZeneca's 7,300 layoffs were not the last word for 2012, Alcon gets hit with an untitled letter from OPDP, and Novo creates an all-diabetic sports team
 

BMS, Abbott HCV pill data suggest competition for Gilead

October 16, 2012

Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.
 

Boehringer bails out of virology R&D

September 18, 2012

Boehringer Ingelheim is getting out of virology and will shut down a Quebec research facility, eliminating 170 positions in the process.
 

For drug pipelines, more limp than leap, report says

September 10, 2012

With all the new and novel medicines launched the last couple of years, one would think pharma pipelines are gradually improving. Not so fast, says a new analyst report.
 

Past the patent cliff, pharmas are set for rebound in NMEs, says IMS

July 12, 2012

Industry pipelines might not be brimful of blockbusters, but after years of meager output, biopharma firms are poised to tap a cornucopia of innovative treatments as thirty-something New Molecular Entities launch each year through 2016.
 

Company news: Roche, Porter Novelli

June 27, 2012

Roche shutters its Nutley, NJ, R&D site, and Porter Novelli names a new CEO.
 

Genentech expands Alzheimer's partnership with AC Immune

June 18, 2012

New deal will provide "bookend" targeting to Genentech's Alzheimer's portfolio.
 

PhRMA's Washington wish list

May 21, 2012

PhRMA presented Washington with its legislative wish list - and a warning that plenty of other countries are trying to woo the industry away from the US.
 

Takeda looks to build vaccines business

December 06, 2011

Takeda is getting into vaccines with the launch of a dedicated global division that will make use of Nycomed A/S's business infrastructure in Europe and emerging markets.
 

Since Vioxx scare, tough times for industry R&D, study finds

December 01, 2011

A review of 450 New Molecular Entities spanning a decade and a half found two distinct eras of drug R&D - one of abundance and one of scarcity, hinging on the September, 2004 withdrawal of Merck's Vioxx.
 

Eliquis stacks up better than Pradaxa or Xarelto

August 30, 2011

Eliquis has demonstrated, in convincing fashion, that it's superior in efficacy and bleeding profile to standard warfarin therapy, and neither Pradaxa nor Xarelto can match it in overall mortality or safety.
 

European meeting may clear the air on Eliquis

August 23, 2011

Experts are looking forward to an international cardiology meeting this weekend to help answer a key question: Will Eliquis become the leading substitute for warfarin?
 

Results of heart study bring Bydureon back from brink, analyst says

July 08, 2011

The results, showing the long-acting diabetes med had passed a crucial test of its effects on heart rhythms, put the drug back on track after a spate of regulatory delays, wrote one analyst.
 

Pfizer's radical surgery looking more like a $5 billion nip and tuck

July 07, 2011

Pfizer took a big step back from plans for a radical streamlining, announcing plans to look at spinning off or selling its Animal Health and Nutrition businesses but not the much larger Established Products unit or its Consumer Healthcare portfolio.
 

Company news: EvaluatePharma and Citeline

June 28, 2011

Years after generic competition begins eroding Lipitor revenues (and RA biologic Humira overtakes it as the world's biggest selling drug), Pfizer will still be the industry's sales leader, but Sanofi and Novartis will run closely behind, according to EvaluatePharma's World Preview 2016.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising Allergy Anaphylaxis Anti-infective App ASCO Centers For Disease Control Diabetes Digital Marketing DTC Elan FDA Generic Generic Drugs Lymphoma Marketing & Communications Mobile Oncology Patient Advocacy Pipeline Regulatory Research & Development Roche